- Home
- MTX vs HCM Comparison
MTX vs HCM Comparison
Compare MTX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTX | HCM |
|---|---|---|
| Founded | 1968 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | MTX | HCM |
|---|---|---|
| Price | $67.59 | $16.04 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $79.67 | $13.75 |
| AVG Volume (30 Days) | ★ 167.2K | 59.0K |
| Earning Date | 01-29-2026 | 08-07-2025 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | ★ $2,071,200,000.00 | $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.02 | $15.54 |
| P/E Ratio | ★ N/A | $5.89 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.54 | $11.51 |
| 52 Week High | $78.23 | $19.50 |
Technical Indicators
Market Signals| Indicator | MTX | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 72.08 | 75.72 |
| Support Level | $65.82 | $14.63 |
| Resistance Level | $68.24 | $15.00 |
| Average True Range (ATR) | 1.59 | 0.42 |
| MACD | 0.40 | 0.26 |
| Stochastic Oscillator | 87.42 | 90.63 |
Price Performance
Historical ComparisonAbout MTX Minerals Technologies Inc.
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.